Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus Neoadjuvant Chemotherapy in HR+/HER2- Breast Cancer
NCT06977893Phase 3Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Mar 2025
- Primary completion
- Mar 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab in breast cancer, sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Started Mar 2025; status: recruiting.
02
Drugs
toripalimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06977893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06977893.